Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol
Manuscript Number:
18-0634R2
Author(s):
Kristin J. Adams, Deborah E. Barnes, Sascha Dublin, Allison R. Kaup, Eric B. Larson, Evette J. Ludman, Carrie B. Peltz, Anne D. Renz, Dori Rosenberg, Eric Vittinghoff, Kristine Yaffe
Disclosures
Kristin J. Adams
Nothing to Disclose
Deborah E. Barnes
Grants
Agency:
Together Senior Health, Inc.
Dates:
9/30/18 - 6/30/19
Sascha Dublin
Equity:
I do own stocks but I do not manage my own portfolio; it is managed by a financial advisor who has been instructed to avoid pharmaceutical and healthcare stocks.
Grants
Agency:
Jazz Pharmaceuticals
Dates:
2/1/2018-5/30/2019
Allison R. Kaup
Consulting Fees:
Scientific advisor for Squint Metrics
Eric B. Larson
Consulting Fees:
UpToDate - evidence-based, clinical decision support resource.
Evette J. Ludman
Nothing to Disclose
Carrie B. Peltz
Nothing to Disclose
Anne D. Renz
Nothing to Disclose
Dori Rosenberg
Nothing to Disclose
Eric Vittinghoff
Equity:
Equities:
CVS Health $30,067
Johnson & Johnson $23,896
Merck, $1082
Novo Nordisk $24,379
Other equities in non-health related companies: $430,082
Kristine Yaffe
Consulting Fees:
I serve on several DSMBs for both the NIH and industry. None have any content overlap or conflict with this manuscript or protocol.